Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avacta GroupAVCTF 17 3-Year EBITDA Growth Rate is 20.80% as of Dec. 2025, which is 134% above its 10-year median of 8.90. GuruFocus rates AVCTF with a GF Score™ of 17/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,136 Biotechnology companies, Avacta Group ranks better than 57.13% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 9.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -13.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Avacta Group was 60.80% per year. The lowest was -286.20% per year. And the median was 8.90% per year.
Avacta Group (OTCPK:AVCTF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Avacta Group 3-Year EBITDA Growth Rate Related Terms
AVCTF vs VRTX, REGN, ALNY: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Avacta Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Avacta Group's 3-Year EBITDA Growth Rate falls into.
Avacta Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.80% mean?
Avacta Group (AVCTF) has a 3-Year EBITDA Growth Rate of 20.80% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Avacta Group and its competitors. This is 134% above median its historical median of 8.90. According to the industry distribution chart, Avacta Group ranks #487 out of 1136 companies in the Biotechnology industry, placing it in the top 42.9%.
Is Avacta Group's 3-Year EBITDA Growth Rate too high?
Avacta Group's current 3-Year EBITDA Growth Rate of 20.80% is 134% above median its 10-year median of 8.90. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.95. Avacta Group's value of 20.80% is 39.1% above this industry median. Based on the distribution chart, Avacta Group ranks #487 out of 1136 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Avacta Group has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #487 out of 1136 companies for 3-Year EBITDA Growth Rate. This puts Avacta Group in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.95. Avacta Group's value of 20.80% is 39.1% above this benchmark. While the company's 10-year median is 8.90 vs. the industry median of 14.95, Avacta Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.95, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avacta Group's current 3-Year EBITDA Growth Rate of 20.80% is 39.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Avacta Group and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avacta Group's current 3-Year EBITDA Growth Rate is 20.80%, which is 134% above median its own 10-year median of 8.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (AVCTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $0.91 — trading 39.4% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 20.80%, which is 134% above median its 10-year median of 8.90 and 39.1% above the Biotechnology industry median of 14.95. Avacta Group's overall GF Score™ is 17/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Avacta Group (AVCTF), the current 3-Year EBITDA Growth Rate is 20.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (AVCTF) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of $0.91 is trading 39.4% above its estimated GF Value™ of $0.65.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for AVCTF:
3-Year EBITDA Growth Rate: 20.80% (134% above median its 10-year median of 8.90)
GF Value™: $0.65 vs. price of $0.91 (39.4% above fair value)
Industry Position: 39.1% above the Biotechnology median (#487 of 1136)
No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
17GF Score
Get the complete analysis for AVCTF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVCTF has been successfully added to your 
